Pharmaceutical Non-Active Ingredients TRIZ Cases

Direct copolymerization yields defined structures that prevent premature leakage, resolving synthesis complexity while maintaining stability.

Combines a PARP inhibitor with a long-acting topoisomerase I inhibitor to target cancer cells through multiple pathways simultaneously.

Styrene-modified elastomeric compounds maintain physical properties during gamma irradiation, preventing deterioration of pharmaceutical stoppers.

Antioxidants and pH modifiers suppress nitrosamine formation to meet FDA limits.

Segmenting active substances prevents incompatibility while disintegrants ensure rapid dissolution.

Comparing interfacial tension decreases identifies lubricant interactions to prevent protein degradation in prefilled injection devices.

A synthetic copolymer conjugate carries affinity tags, imaging probes, and targeting ligands to bind proteins.

A film coating composition uses polyvinyl alcohol with a specific hydrolysis degree to reduce tablet stickiness during the coating process.

Segmented organic solvent injection and dynamic stirring enable scalable production of homogeneous adjuvant formulations with consistent particle size.

Zwitterion polymer conjugates link therapeutic polypeptides to inhibit aggregation, maintaining efficacy while avoiding toxicity from protein clumping.

Segmented PBD conjugates exploit differential folate receptor expression to selectively deliver toxins, reducing host toxicity.

Dry-heat amorphization de-clusters starch before ultrasonic complexing with amino acids to form VI-type crystals.

Cyclooctyne click chemistry attaches payloads to antibodies, resolving heterogeneous drug loading and off-target toxicities.

Cyclodextrin coatings on charged cores coordinate drug release kinetics to resolve pharmacokinetic mismatches and non-specific tissue accumulation.

Oxyma and DIC coupling agents synthesize hyaluronan-drug conjugates in a homogeneous DMSO reaction phase.

Carbamate linkages in polymeric reagents enable customizable hydrolysis rates, extending drug half-life while reducing immunogenicity.

Segmented antibodies targeting distinct CD3 chains improve treatment efficacy for TCR-CD3 diseases while minimizing off-target effects.

Rotary moulding machines produce uniform soft chews weighing 2g or less, resolving size and weight inconsistencies of conventional pressure systems.

Conjugates retain effector function by binding to Fc-gamma receptors, resolving the trade-off between targeted delivery and immune cell activation.

Hyaluronic acid grafted with dextran tyramine uses enzymatic crosslinking to resolve slow gelation and cytotoxicity from photo-initiators.

A segmented adhesive matrix stabilizes a supersaturated active agent, preventing precipitation while maintaining high drug permeation rates across the skin.

Oxybate-polyethylene glycol ester prodrugs extend plasma detection via controlled hydrolysis, reducing toxicity and abuse potential in narcolepsy treatment.

Antibody medicant conjugates deliver cytotoxic payloads via selective receptor binding, resolving systemic toxicity trade-offs in solid tumor treatment.

Prevents crystallization of slightly water-soluble active substances by maintaining molecular dispersion in composite polymer matrices.